Rituximab as front-line treatment in refractory autoimmune hemolytic anemia

Moriki, Dafni; Karalexi, Maria A.; Kekkou, Kassiani; Kalogiannis, Michalis; Papaevangelou, Vassiliki; Petrocheilos, Ioannis

doi:10.23736/s0026-4946.19.05672-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab is a genetically engineered monoclonal antibody directed against CD20 antigen, is seen in a certain subset of B-cells, and causes significant B-cell depletion. Rituximab has shown good efficacy in many autoimmune hematologic disorders together with low or absent toxicity ( 13 , 14 ) and has already been administered in other cases of PRCA ( 15 , 16 ). Cases of epoetin-related PRCA treated with rituximab which succeeded or failed had been reported ( 17 , 18 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Roxadustat in Combination With Rituximab Was Used to Treat EPO-Induced Pure Red Cell Aplasia

You¹,

Guo²,

Wang³

et al. 2022

Front. Nephrol.

View full text Add to dashboard Cite

Recombinant human erythropoietin (rHuEPO) is a drug given to patients who have low hemoglobin related to chronic kidney disease or other anemia-related diseases. Some patients who receive rHuEPO repeatedly develop anti-rHuEPO-neutralizing antibodies, leading to the occurrence of pure red cell aplasia (PRCA). PRCA associated with rHuEPO includes severe rHuEPO resistance, blood transfusion dependence, high serum ferritin, severe reticulocytopenia, and presence of anti-rHuEPO antibody. However, the optimal treatment of erythropoietin (EPO)-induced PRCA is unclear. Therapeutic options against it remain a major clinical challenge. Herein we report on 2 male patients with PRCA during rHuEPO treatment, who received a combination therapy of roxadustat plus rituximab but had completely different clinical outcomes. The results obtained in this study show that roxadustat in combination with rituximab could be one of the treatment options for EPO-induced PRCA, but the treatment efficacy can vary from one individual to another. Additionally, we recommend starting reticulocyte monitoring and immunosuppressive agent therapy as early as possible to shorten the course of the disease and improve the outcomes of the patients.

show abstract